 Hideyuki Nakanishi
Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| RNA, Messenger | 8 | 2025 | 2679 | 1.890 |
Why?
| | Synthetic Biology | 2 | 2021 | 13 | 1.330 |
Why?
| | RNA | 3 | 2022 | 881 | 1.320 |
Why?
| | Mammals | 3 | 2022 | 269 | 1.320 |
Why?
| | Viral Proteins | 3 | 2020 | 323 | 1.230 |
Why?
| | Transfection | 6 | 2022 | 896 | 1.210 |
Why?
| | Genetic Vectors | 4 | 2017 | 311 | 1.200 |
Why?
| | Gene Regulatory Networks | 2 | 2020 | 281 | 1.110 |
Why?
| | Protein Biosynthesis | 4 | 2024 | 398 | 1.060 |
Why?
| | MicroRNAs | 4 | 2021 | 674 | 0.990 |
Why?
| | DNA Transposable Elements | 3 | 2011 | 118 | 0.960 |
Why?
| | Light | 2 | 2021 | 353 | 0.850 |
Why?
| | Metal Nanoparticles | 6 | 2022 | 82 | 0.830 |
Why?
| | Single-Domain Antibodies | 1 | 2022 | 5 | 0.780 |
Why?
| | Cell Differentiation | 3 | 2021 | 1900 | 0.760 |
Why?
| | Proteins | 3 | 2022 | 936 | 0.750 |
Why?
| | Pluripotent Stem Cells | 2 | 2021 | 78 | 0.740 |
Why?
| | Crowdsourcing | 1 | 2020 | 18 | 0.700 |
Why?
| | Caliciviridae | 1 | 2020 | 1 | 0.680 |
Why?
| | Consumer Behavior | 1 | 2020 | 67 | 0.680 |
Why?
| | Flow Cytometry | 3 | 2021 | 1142 | 0.670 |
Why?
| | User-Computer Interface | 1 | 2020 | 148 | 0.660 |
Why?
| | Cell Separation | 1 | 2021 | 312 | 0.650 |
Why?
| | Robotics | 1 | 2020 | 90 | 0.640 |
Why?
| | Gold | 7 | 2022 | 118 | 0.640 |
Why?
| | Genetic Therapy | 3 | 2025 | 292 | 0.620 |
Why?
| | RNA-Binding Proteins | 1 | 2021 | 389 | 0.560 |
Why?
| | Electric Capacitance | 1 | 2017 | 8 | 0.550 |
Why?
| | Nanowires | 1 | 2017 | 12 | 0.550 |
Why?
| | Genes, Reporter | 1 | 2017 | 266 | 0.510 |
Why?
| | HeLa Cells | 4 | 2022 | 606 | 0.450 |
Why?
| | Nanotechnology | 3 | 2011 | 121 | 0.440 |
Why?
| | Integrases | 1 | 2014 | 118 | 0.430 |
Why?
| | Inteins | 2 | 2024 | 3 | 0.420 |
Why?
| | Bacteriophages | 1 | 2014 | 92 | 0.410 |
Why?
| | Ions | 1 | 2011 | 65 | 0.370 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2011 | 53 | 0.370 |
Why?
| | DNA, Circular | 1 | 2011 | 15 | 0.370 |
Why?
| | Electrons | 1 | 2011 | 78 | 0.370 |
Why?
| | Neuraminidase | 1 | 2010 | 24 | 0.350 |
Why?
| | Guanidines | 1 | 2010 | 36 | 0.350 |
Why?
| | Cyclopentanes | 1 | 2010 | 19 | 0.350 |
Why?
| | Nanostructures | 1 | 2011 | 99 | 0.350 |
Why?
| | Sulfhydryl Compounds | 2 | 2012 | 187 | 0.340 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2010 | 146 | 0.310 |
Why?
| | Photochemistry | 1 | 2009 | 131 | 0.310 |
Why?
| | Protein Processing, Post-Translational | 2 | 2022 | 453 | 0.290 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2010 | 281 | 0.270 |
Why?
| | DNA-Binding Proteins | 1 | 2014 | 1423 | 0.270 |
Why?
| | Induced Pluripotent Stem Cells | 2 | 2019 | 222 | 0.240 |
Why?
| | Nucleic Acid Conformation | 2 | 2020 | 706 | 0.240 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2025 | 41 | 0.240 |
Why?
| | Nanoparticles | 4 | 2025 | 369 | 0.230 |
Why?
| | Gene Expression | 1 | 2010 | 1455 | 0.230 |
Why?
| | Antiviral Agents | 1 | 2010 | 711 | 0.230 |
Why?
| | Influenza, Human | 1 | 2010 | 600 | 0.220 |
Why?
| | Muscular Dystrophy, Duchenne | 1 | 2025 | 89 | 0.220 |
Why?
| | Glycocalyx | 1 | 2022 | 19 | 0.200 |
Why?
| | Ligands | 2 | 2022 | 617 | 0.190 |
Why?
| | Plasmids | 2 | 2014 | 355 | 0.180 |
Why?
| | Electric Conductivity | 2 | 2011 | 94 | 0.170 |
Why?
| | HEK293 Cells | 2 | 2014 | 683 | 0.170 |
Why?
| | Commerce | 1 | 2020 | 67 | 0.170 |
Why?
| | Gene Expression Regulation | 2 | 2020 | 2516 | 0.170 |
Why?
| | Amino Acid Motifs | 1 | 2020 | 211 | 0.160 |
Why?
| | Animals | 6 | 2025 | 34647 | 0.160 |
Why?
| | Mucopolysaccharidosis II | 1 | 2019 | 3 | 0.160 |
Why?
| | Gene Editing | 1 | 2020 | 68 | 0.160 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 930 | 0.160 |
Why?
| | Protein Multimerization | 1 | 2020 | 178 | 0.150 |
Why?
| | Lysosomes | 1 | 2019 | 135 | 0.150 |
Why?
| | Small Molecule Libraries | 1 | 2019 | 86 | 0.150 |
Why?
| | Cell Culture Techniques | 1 | 2021 | 345 | 0.150 |
Why?
| | Humans | 14 | 2024 | 128495 | 0.140 |
Why?
| | Base Sequence | 1 | 2021 | 2137 | 0.140 |
Why?
| | Electric Power Supplies | 1 | 2017 | 49 | 0.130 |
Why?
| | Electrodes | 1 | 2017 | 103 | 0.130 |
Why?
| | Gene Dosage | 1 | 2017 | 142 | 0.130 |
Why?
| | Cells, Cultured | 2 | 2021 | 4017 | 0.130 |
Why?
| | Metals | 1 | 2017 | 126 | 0.130 |
Why?
| | Organic Chemicals | 1 | 2017 | 128 | 0.120 |
Why?
| | Genome | 1 | 2017 | 277 | 0.120 |
Why?
| | Cell Survival | 1 | 2017 | 1076 | 0.110 |
Why?
| | Myocytes, Cardiac | 1 | 2017 | 495 | 0.100 |
Why?
| | Silver | 2 | 2010 | 34 | 0.100 |
Why?
| | Electrochemistry | 1 | 2012 | 80 | 0.100 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1199 | 0.100 |
Why?
| | Metals, Heavy | 1 | 2012 | 30 | 0.100 |
Why?
| | Models, Biological | 1 | 2019 | 1698 | 0.090 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 87 | 0.090 |
Why?
| | Sequence Analysis, DNA | 1 | 2014 | 775 | 0.090 |
Why?
| | Cell Line | 1 | 2017 | 2741 | 0.090 |
Why?
| | Gels | 1 | 2011 | 82 | 0.090 |
Why?
| | Apoptosis | 1 | 2020 | 2437 | 0.090 |
Why?
| | Acids, Carbocyclic | 1 | 2010 | 2 | 0.090 |
Why?
| | Boronic Acids | 1 | 2011 | 37 | 0.090 |
Why?
| | Anemia, Hemolytic, Autoimmune | 1 | 2010 | 15 | 0.090 |
Why?
| | Transcription, Genetic | 1 | 2017 | 1404 | 0.090 |
Why?
| | Environmental Pollutants | 1 | 2012 | 142 | 0.090 |
Why?
| | Prednisolone | 1 | 2010 | 82 | 0.090 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2011 | 112 | 0.080 |
Why?
| | Pyrazines | 1 | 2011 | 86 | 0.080 |
Why?
| | Antineoplastic Agents | 2 | 2011 | 2042 | 0.080 |
Why?
| | Inverted Repeat Sequences | 1 | 2009 | 19 | 0.080 |
Why?
| | Transposases | 1 | 2009 | 16 | 0.080 |
Why?
| | Myelodysplastic Syndromes | 1 | 2011 | 129 | 0.080 |
Why?
| | Mice, Inbred ICR | 1 | 2010 | 108 | 0.080 |
Why?
| | Mutagenesis, Insertional | 1 | 2009 | 65 | 0.080 |
Why?
| | Luciferases | 1 | 2010 | 147 | 0.080 |
Why?
| | Emergencies | 1 | 2010 | 154 | 0.080 |
Why?
| | Chromosomes | 1 | 2009 | 101 | 0.080 |
Why?
| | Multiple Myeloma | 1 | 2011 | 125 | 0.080 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2009 | 74 | 0.080 |
Why?
| | Surface Plasmon Resonance | 1 | 2009 | 88 | 0.080 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2010 | 141 | 0.080 |
Why?
| | Transgenes | 1 | 2009 | 176 | 0.080 |
Why?
| | Renal Insufficiency | 1 | 2011 | 148 | 0.080 |
Why?
| | Immunocompromised Host | 1 | 2010 | 196 | 0.080 |
Why?
| | Acute Lung Injury | 1 | 2011 | 264 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1027 | 0.070 |
Why?
| | Radiography | 1 | 2010 | 795 | 0.070 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2010 | 245 | 0.070 |
Why?
| | Models, Chemical | 1 | 2009 | 263 | 0.070 |
Why?
| | Combined Modality Therapy | 1 | 2010 | 1201 | 0.070 |
Why?
| | Anti-Infective Agents | 1 | 2010 | 245 | 0.070 |
Why?
| | Disease Outbreaks | 1 | 2010 | 347 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2010 | 684 | 0.060 |
Why?
| | Temperature | 1 | 2009 | 632 | 0.060 |
Why?
| | Respiration, Artificial | 1 | 2010 | 604 | 0.060 |
Why?
| | Mice, Inbred mdx | 1 | 2025 | 11 | 0.060 |
Why?
| | Micelles | 1 | 2025 | 37 | 0.060 |
Why?
| | Microscopy, Electron, Transmission | 2 | 2018 | 143 | 0.060 |
Why?
| | Hydrodynamics | 1 | 2025 | 40 | 0.060 |
Why?
| | Adsorption | 2 | 2018 | 139 | 0.060 |
Why?
| | DNA Polymerase III | 1 | 2024 | 8 | 0.060 |
Why?
| | Chondroitin Sulfates | 1 | 2022 | 34 | 0.050 |
Why?
| | Glycosaminoglycans | 1 | 2022 | 84 | 0.050 |
Why?
| | Mice | 2 | 2025 | 16620 | 0.040 |
Why?
| | Surface Properties | 2 | 2011 | 394 | 0.040 |
Why?
| | Bacterial Proteins | 1 | 2024 | 833 | 0.040 |
Why?
| | Biosensing Techniques | 1 | 2018 | 115 | 0.030 |
Why?
| | Male | 4 | 2025 | 63043 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2025 | 1624 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2025 | 3947 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2025 | 5281 | 0.030 |
Why?
| | Ethylene Glycol | 1 | 2012 | 13 | 0.030 |
Why?
| | Molecular Conformation | 1 | 2012 | 142 | 0.020 |
Why?
| | Autopsy | 1 | 2011 | 92 | 0.020 |
Why?
| | Bortezomib | 1 | 2011 | 45 | 0.020 |
Why?
| | Creatine | 1 | 2011 | 55 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2011 | 301 | 0.020 |
Why?
| | Rituximab | 1 | 2011 | 162 | 0.020 |
Why?
| | Spectrophotometry | 1 | 2010 | 58 | 0.020 |
Why?
| | Particle Size | 1 | 2011 | 352 | 0.020 |
Why?
| | Static Electricity | 1 | 2010 | 116 | 0.020 |
Why?
| | Dimethylpolysiloxanes | 1 | 2009 | 10 | 0.020 |
Why?
| | Cross-Linking Reagents | 1 | 2009 | 205 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2010 | 352 | 0.020 |
Why?
| | Adult | 1 | 2010 | 35299 | 0.020 |
Why?
| | Biopsy | 1 | 2011 | 1079 | 0.020 |
Why?
| | Models, Molecular | 1 | 2012 | 1484 | 0.020 |
Why?
| | Escherichia coli | 1 | 2010 | 771 | 0.020 |
Why?
| | Female | 2 | 2011 | 68266 | 0.020 |
Why?
| | Oxygen | 1 | 2010 | 901 | 0.010 |
Why?
| | Aged | 2 | 2011 | 21974 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2011 | 2517 | 0.010 |
Why?
| | Middle Aged | 1 | 2011 | 30921 | 0.010 |
Why?
|
|
Nakanishi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|